IV Ensure in Patients Receiving OPAT

Part of paid clinical trials in Oklahoma City, Oklahoma.

Sponsor
IV Ensure
Study ID
NCT06623318
Status
Recruiting
Apply to this trial

Conditions

  • Determine If Adherence Rates with IV Antibiotics in OPAT Have a Correlation to Hospital Readmission Rates

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Remote therapeutic monitoring device — DEVICE
    IV Ensure proprietary remote therapeutic monitoring device is used to record and transmit data associated with date, time, and duration of IV medications administered in the home setting post-acute.

Study Details

The purpose of remote therapeutic monitoring is to provide oversight and evaluation of patients receiving IV medications in the home setting post-acute. The goal is to improve patient outcomes and decrease re-admission rates for related diagnoses due to poor adherence. Remote therapeutic monitoring provides data used in the determination of dates, times, and duration of doses administered in the home setting to support real-time intervention by dedicated care managers to support improved adherence with prescribed dosing regiments. The objectives of the study are to: 1. Determine adherence rates for IV medications administered in the home. 2. Assess re-admission against adherence rates.

Key Dates

Start date
Aug 23, 2023
Status verified
Sep 2024
Primary completion
Oct 15, 2024
Completion
Nov 30, 2024

Study Design

Enrollment
90 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH

Arms

  • Experimental: Determine adherence rate for IV medications administered in the home.
    Patients will be assigned IV Ensure's remote therapeutic monitoring device to determine their adherence rate with administration of IV medications administered in the home in comparison to their provider's orders.
  • Experimental: Assess re-admission against adherence rates.
    Assess correlation of patients hospital re-admission rates for infection related disease progression associated with adherence rates of IV medications administered in the home.

Primary Outcome Measure

Readmission due to subsequent related infection following the initial encounter. [ Time Frame: From enrollment to 30 days after completion of prescribed IV medication. ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
The University of Oklahoma Health Sciences CenterOklahoma CityOklahoma73104
Joseph Sassine, MD, FACP
[email protected]
405-271-6122
Brittany Karfonta
[email protected]
405-271-3480
Joseph Sassine, MD, FACP

Find similar trials in Oklahoma City, OK

By research site
The University of Oklahoma Health Sciences Center· Oklahoma City, OK